Pharmacovigilance

Pharmacovigilance is the discipline of detecting, assessing, understanding and preventing adverse effects of medicinal products, mature in pharmaceuticals under ICH E2A through E2F, EU Good Pharmacovigilance Practices (GVP) and the FDA Office of Surveillance and Epidemiology, and increasingly adopted by mature dietary supplement brand-owners as a discipline beyond the DSNDCPA reporting minimum. Pharmacovigilance converts individual case reports into population-level safety knowledge through systematic case quality review, causality assessment, aggregation and quantitative signal detection, periodic safety summarisation, risk management planning and continuous learning feeding back into formulation, labelling and supplier qualification.

Causality assessment uses published frameworks — the WHO-UMC (Uppsala Monitoring Centre) categorisation (Certain, Probable/Likely, Possible, Unlikely, Conditional, Unassessable) based on temporal relationship, plausibility, dechallenge, rechallenge, alternative explanations and concomitant medication review; or the Naranjo Adverse Drug Reaction Probability Scale, a 10-item weighted questionnaire yielding Definite/Probable/Possible/Doubtful classification. Supplement adaptation accounts for multi-ingredient products, multi-product concomitant use, ethically constrained rechallenge data and weaker follow-up infrastructure compared with prescription pharmaceuticals, typically defaulting to 'Possible' or 'Conditional' classifications where ambiguity is structural.

Signal detection uses quantitative methods (Proportional Reporting Ratio, Reporting Odds Ratio, Information Component from Bayesian Confidence Propagation Neural Network) where dataset scale supports, and qualitative methods (ingredient-cluster analysis, lot-cluster analysis, formulation-change correlation) at any scale. Periodic Safety Update Reports (PSURs) under ICH E2C(R2) are mandatory for pharmaceuticals; supplement-adapted periodic safety summaries are voluntary in the US but increasingly required by international regulators (Health Canada NHP, EU member state Nutrivigilance systems, TGA listed medicines). Risk Management Plans structure identified risks, potential risks, missing information, routine and additional risk minimisation measures, and effectiveness measurement — increasingly adopted for botanical actives, sports nutrition with anabolic-adjacent considerations, weight management products with cardiovascular concerns, and any product where the AER dataset has surfaced signals worth structured management. PV infrastructure is increasingly expected by retailers, insurance carriers and plaintiff law firms evaluating brand-owner negligence — the absence of PV is a defensible liability gap, not a neutral cost saving.